<i>In vivo</i> screening of subcutaneous tolerability for the development of novel excipients.

In vivo screening of subcutaneous tolerability for the development of novel excipients.

Takai, Yuichi; Powlin, Stephanie; Awasaki, Yasuyuki; Yamauchi, Toshiaki; Sano, Tomoya; Takahashi, Haruyuki; Ranneh, Abdul-Hackam; Arai, Yuta.

Afiliação

Takai Y; Drug Safety Research and Evaluation, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2 Chome, Fujisawa, Kanagawa 251-8555, Japan.
Powlin S; Drug Safety Research and Evaluation, Takeda Pharmaceutical International Co., 40 Landsdowne Street, Cambridge, MA, 02139, USA.
Awasaki Y; Drug Safety Research and Evaluation, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2 Chome, Fujisawa, Kanagawa 251-8555, Japan.
Yamauchi T; Drug Safety Research and Evaluation, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2 Chome, Fujisawa, Kanagawa 251-8555, Japan.
Sano T; Drug Safety Research and Evaluation, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2 Chome, Fujisawa, Kanagawa 251-8555, Japan.
Takahashi H; Pharmaceutical Sciences, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2 Chome, Fujisawa, Kanagawa 251-8555, Japan.
Ranneh AH; Pharmaceutical Sciences, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2 Chome, Fujisawa, Kanagawa 251-8555, Japan.
Arai Y; Pharmaceutical Sciences, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2 Chome, Fujisawa, Kanagawa 251-8555, Japan.

J Toxicol Pathol ; 35(4): 355-360, 2022 Oct.

Article em En | MEDLINE | ID: mdl-36406168